Brana Vita is rich in arabinoxylan oligosaccharides (AXOS), soluble fibers derived from the cell walls of wheat bran.
The AXOS are potent prebiotics which stimulates the growth of beneficial colon bacteria such as bifidobacteria, and due to the presence of AXOS-bound polyphenols also produce antioxidant activity.
The approval allows the use of Brana Vita with a 3 g dose per serving in a range of functional food categories such as breakfast cereals, dairy products and drinks.
The company is continuing its efforts to create additional clinical and safety data to support extension of EU Novel Food Approval to other applications in the future.
Fugeia MD and co-founder Willem Broekaert said winning key regulatory approvals has been a significant element in building a strong platform for commercial launch.